Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9612 posts found.

opdivo_1

Opdivo to go before EU, US regulators in head and neck cancer

July 19, 2016 Manufacturing and Production, Research and Development EMA, EU, FDA, US, head and neck cancer, opdivo

Bristol-Myers Squibb has announced that its lead oncology drug, Opdivo (nivolumab), is set to go before regulators in the US …
News
novartis_side_building

Novartis lowers core operating profit outlook in Q2 results

July 19, 2016 Manufacturing and Production, Research and Development, Sales and Marketing 2016, Novartis, Q2, results

Novartis has warned that its profits may decline this year as it issued second quarter results, with generic competition for …
News
triumeq-image-pill-bottle

New data shows superior viral suppression for Triumeq in women with HIV

July 18, 2016 Manufacturing and Production, Research and Development Triumeq, ViiV Healthcare

ViiV Healthcare has presented late-stage data showing superior efficacy for combination treatment Triumeq (dolutegravir/abacavir/lamivudine) compared with atazanavir, plus other treatments, …
News
astrazeneca-sign

AstraZeneca presents positive Phase III results for lung cancer drug Tagrisso

July 18, 2016 Manufacturing and Production, Research and Development AstraZeneca, Tagrisso

AstraZeneca has presented results from the latest Phase III trial evaluating Tagrisso (osimertinib) as a second line treatment for patients …
News
roche__tree

Roche’s lymphoma drug fails to beat rivals in Phase III trial

July 18, 2016 Research and Development, Sales and Marketing Roche, lymphoma, phase III

Roche has announced that a Phase III trial evaluating Gazyva/Gazyvaro (obinutuzumab) in patients with previously untreated diffuse large B-cell lymphoma …
News
samsung

Samsung Bioepis Humira biosimilar gets accepted for EMA review

July 18, 2016 Research and Development, Sales and Marketing EMA, Humira, Samsung Bioepis, application

The European Medicines Agency (EMA) has accepted for review the marketing authorisation application from Samsung Bioepis for their biosimilar version …
News

FDA approves first extended depth of focus lenses for people with cataracts

July 18, 2016 Research and Development, Sales and Marketing Abbott, FDA, cataracts

Abbott has announced that the Tecnis Symfony Intraocular Lenses for the treatment of cataracts has been approved by the US …
News
fda_sign_web

Valeant’s psoriasis drug “difficult to assess”, according to FDA staff

July 18, 2016 Research and Development, Sales and Marketing FDA, Valeant, psoriasis

Staff at the US Food and Drug Administration have expressed concerns over Valeant’s psoriasis candidate, brodalumab, due to the potential …
News
clinical_trial_4

Patient death in gene therapy trial sends Ziopharm stocks falling

July 18, 2016 Research and Development, Sales and Marketing ziopharm

Ziopharm Oncology has issued a statement following the death of a patient enrolled on a Phase I clinical trial for …
News
msd

UK medical charity sells part of interest in MSD’s Keytruda for $150 million

July 15, 2016 Research and Development, Sales and Marketing MSD, Merck, keytruda

UK medical research charity MRC Technology sold part of its royalty interest in US pharma major MSD’s (NYSE: MRK) immunotherapy …
News
stocks1

Weekly Movers: CytRx, Coherus BioSciences, Juno Therapeutics…

July 15, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Coherus BioSciences, GW Pharmaceuticals, Sage Therapeutics, Share price, Shares, Stock Markets, cytrx, juno therapeutics

Shares in CytRx (Nasdaq: CYTR) lost nearly three-fourth in value after the company reported disappointing late-stage results for its lead …
Feature

Nice rejects United Therapeutics’ cancer drug

July 15, 2016 Medical Communications, Research and Development NICE, United Therapeutics, Unituxin, neuroblastoma

The National Institute for Health and Care Excellence (Nice) rejected United Therapeutics’ (Nasdaq: UTHR) Unituxin (dinutuximab) in combination therapy to …
News

Busy week at Juno Therapeutics ends with takeover of RedoxTherapies

July 15, 2016 Medical Communications, Research and Development, Sales and Marketing juno therapeutics, redoxtherapies, takeover, vipadenant

Juno Therapeutics (NASDAQ: JUNO) has announced the acquisition of RedoxTherapies, adding its lead cancer drug candidate, vipadenant, to its portfolio.
News
lab

Shares drop at Santhera after FDA requires more trial data DMD drug

July 15, 2016 Medical Communications, Research and Development Duchenne Muscular Dystrophy, FDA, santhera

Santhera Pharmaceuticals (SIX: SANN) has seen shares fall as much as 38% after the US Food and Drug Administration (FDA) …
News
celgene_1_02

Celgene says its Revlimid gets European approval to treat rare non-Hodgkin’s lymphoma

July 15, 2016 Medical Communications, Research and Development, Sales and Marketing Celgene, European Commission, Revlimid, drug approval, drug trial, oncology

Celgene (Nasdaq: CELG) said the European Commission (EC) has approved Revlimid (lenalidomide) to treat a rare form of non-Hodgkin’s lymphoma. 
News
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026